Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
16
04
2023
accepted:
31
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
This study investigated the changes in serum tumor marker levels in patients with breast cancer (BC) after neoadjuvant chemotherapy (NACT) and their potential as prognostic factors in NACT. A total of 134 consecutive patients with BC treated at our hospital between January 2019 and December 2021 were retrospectively analyzed. Patients were treated with NACT based on the docetaxel, epirubicin, and cyclophosphamide (TEC) regimen and assessed for marker levels, T cell subsets, and therapeutic outcomes. Receiver operating characteristic (ROC) curves were constructed to evaluate the predictive performance of the markers. Outcome assessments showed that NACT effectively reduced the tumor size, leading to increased complete remission, partial remission, stable disease, and significantly reduced disease progression. Improved immune function has also been observed after NACT. The levels of two (E-cadherin and HMGB1) out of five markers (CA153, CK19, CEA, E-cadherin, and HMGB1) were significantly reduced after NACT before surgery compared with those at admission, suggesting that NACT modulates the levels of biomarkers. ROC analysis revealed that the area under the curve (AUC) of HMGB1 and E-cadherin combination was 0.87 for discrimination of therapeutic response with a sensitivity and specificity of 91.3% and 88.4%, respectively. Serum tumor marker levels were reduced after NACT in patients with BC. The reduction was most prominent for HMGB1, followed by E-cadherin. These biomarkers can be used to predict the therapeutic response to NACT with an AUC of 0.87, thus offering a new tool to monitor treatment progress in NACT for patients with BC.
Identifiants
pubmed: 37684327
doi: 10.1038/s41598-023-41836-5
pii: 10.1038/s41598-023-41836-5
pmc: PMC10491604
doi:
Substances chimiques
HMGB1 Protein
0
Cadherins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14791Informations de copyright
© 2023. Springer Nature Limited.
Références
Cancer Med. 2016 Sep;5(9):2350-8
pubmed: 27457217
Biomark Med. 2012 Oct;6(5):629-32
pubmed: 23075240
Lancet Oncol. 2016 Jan;17(1):90-8
pubmed: 26617202
Eur J Cancer. 2001 Feb;37(3):355-63
pubmed: 11239757
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433
pubmed: 32606609
Prog Mol Biol Transl Sci. 2019;162:213-227
pubmed: 30905451
Histopathology. 2016 Aug;69(2):239-49
pubmed: 26708058
Biomed Pharmacother. 2017 Mar;87:8-19
pubmed: 28040600
Clin Breast Cancer. 2017 Apr;17(2):91-99.e1
pubmed: 27756583
Breast Cancer Res. 2003;5(2):89-95
pubmed: 12631387
Tumour Biol. 2013 Feb;34(1):81-90
pubmed: 22983919
Br J Cancer. 2021 Mar;124(7):1286-1293
pubmed: 33473167
Expert Opin Drug Saf. 2014 Nov;13(11):1443-67
pubmed: 25244502
Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7
pubmed: 35243878
Adv Exp Med Biol. 2019;1152:51-64
pubmed: 31456179
Onco Targets Ther. 2015 Feb 12;8:413-9
pubmed: 25709474
Oncol Lett. 2015 Apr;9(4):1922-1926
pubmed: 25789069
Arch Gynecol Obstet. 2022 Apr;305(4):913-920
pubmed: 34510244
Biomark Cancer. 2016 Apr 28;8:57-63
pubmed: 27147896
Clin Chim Acta. 2017 Jul;470:51-55
pubmed: 28457854
Med Sci Monit. 2014 Dec 23;20:2776-82
pubmed: 25553984
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
Chin Clin Oncol. 2020 Jun;9(3):27
pubmed: 32192349
Front Immunol. 2022 May 19;13:877825
pubmed: 35663978
Curr Treat Options Oncol. 2014 Mar;15(1):86-98
pubmed: 24306808
Adv Exp Med Biol. 2015;867:197-225
pubmed: 26530368
Indian J Cancer. 2016 Jan-Mar;53(1):29-33
pubmed: 27146734
Clin Cancer Res. 2017 Jan 1;23(1):214-224
pubmed: 27401250
Anticancer Res. 2001 Nov-Dec;21(6A):4105-8
pubmed: 11911301
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
J Clin Oncol. 2016 Apr 1;34(10):1134-50
pubmed: 26858339
J Mol Evol. 1993 May;36(5):458-76
pubmed: 8510179
Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):190-195
pubmed: 26657871
Clin Exp Med. 2023 Feb;23(1):1-16
pubmed: 35031885
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
J Natl Cancer Inst Monogr. 2001;(30):96-102
pubmed: 11773300
Anticancer Res. 2005 May-Jun;25(3c):2519-25
pubmed: 16080487
Mol Oncol. 2022 Jun;16(12):2312-2329
pubmed: 34890102
Ann Surg Oncol. 2018 Jul;25(7):1783-1785
pubmed: 29671136
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Eur J Cardiothorac Surg. 2011 Jun;39(6):1028-32
pubmed: 21376622